PDCD1 and metastatic melanoma: Taken together, these analyses suggest that hypoalbuminemia is a strong prognostic biomarker for poor outcome of PD-1 blockade in metastatic melanoma, which holds independent prognostic value when considered in conjunction with elevated LDH levels.